The latest market report published by Credence Research, Inc. “Global Premature Ejaculation Treatment Market By Drug Class (Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors, Others), By Route Of Administration (Oral Route, Topical Route)- Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global market for premature ejaculation treatment was estimated at US$ 1,666.1 million in 2017 and is expected to reach US$ 3,541.4 million by 2026, increasing to CAGR by 8.8% from 2018 to 2026.
Browse the full report at “Premature Ejaculation Treatment Market”
The etiology of premature ejaculation is not obviously known. The theories that have been postulated for the incidence of premature ejaculation in males are fast masturbation during adolescence, performance anxiety, lower sexual experience, and passive aggressiveness. However, with little or no proof, these theories are endorsed. Urologists around the globe think that the nucleus paragigantocellularis of the neuronal cells is engaged in premature ejaculation. It creates emotional stress and connection to the patient and his sexual partner. It may be classified as primary or lifelong premature ejaculation and acquired or secondary premature ejaculation. Other variables that may trigger premature ejaculation are inflammation of the prostate or urethra, hereditary characteristics, and abnormal concentrations of neurotransmitters. Tremendous technological advances have taken place in the research and development formulation section to provide drugs with maximum efficacy and minimal side effects.
Currently selective serotonin reuptake inhibitors dominate the market for premature ejaculation therapy. It includes drugs such as sertraline, paroxetine, fluoxetine and citalopram. It has a quick response as it decreases serotonin uptake in presynaptic neuronal cells and improves serotonin concentration in post-synaptic receptor cells, thereby delaying intravaginal ejaculation. Topical anesthetic agents will show outstanding development during the forecast period due to their accessibility as creams, sprays and condoms that provide climax control by regulating the afferent-efferent reflex pathway and delaying ejaculation.
Oral route of administration is preferred for patients with premature ejaculation disorder due to quicker onset of intervention and is common among urologists to prescribe for the treatment of severe premature ejaculation disorder. Topical route of administration is growing at a fast rate owing to improved patient compliance and efficiency in increasing ejaculation latency by decreasing the sensitivity of the penis gland.
Rising prevalence of relationship problems, sexual performance anxiety and illicit drug abuse controls the premature ejaculation treatment market growth in North America. Asia Pacific will be performing with excellent market growth owing to key factors such as rising public awareness regarding premature ejaculation and availability of generic drugs at lower price.
The major players providing medications for treatment of premature ejaculation are Absorption Pharmaceuticals, AstraZeneca, Allergan Plc, Bayer AG, Eli Lilly & Company, GlaxoSmithkline Plc, Innovus Pharmaceuticals, Merck & Co., Inc., Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.
Download Free PDF Sample Request: Premature Ejaculation Treatment Market
Key Market Movements:
- Increasing number of patients suffering with premature ejaculation disorders
- Technological advancement in the preparation of anesthetic agents such as aerosol sprays and condoms to increase intravaginal latency time
- Rising public awareness regarding premature ejaculation in both patients and physicians
By Drug Class (2016–2026; US$ Mn)
Serotonin Uptake Inhibitors
Type 5 Inhibitors
- Others (Beta-adrenergic Blocker, Opioid Analgesic)
- By Route of Administration (2016–2026; US$ Mn)
By Geography Segment (2016–2026; US$ Mn)
- North America
- Asia Pacific (APAC)
- Middle East & Africa (MEA)
- Latin America